Abstract:Human cytochrome P450 1B1 enzyme (hCYP1B1), a member of hCYP1 subfamily, plays a crucial role in multiple diseases by participating in many metabolic pathways. Although a suite of potent hCYP1B1 inhibitors have been previously reported, most of them also act as aryl hydrocarbon receptor (AhR) agonists that can up-regulate the expression of hCYP1B1 and then counteract their inhibitory potential in living systems. This study aimed to develop novel efficacious hCYP1B1 inhibitors that worked well in living cells but without AhR agonist effects. For these purposes, a series of 1,8-naphthalimide derivatives were designed and synthesized, and their structure-activity relationships (SAR) as hCYP1B1 inhibitors were analyzed. Following three rounds SAR studies, several potent hCYP1B1 inhibitors were discovered, among which compound 3n was selected for further investigations owing to its extremely potent anti-hCYP1B1 activity (IC50 = 0.040 nM) and its blocking AhR transcription activity in living cells. Inhibition kinetic analyses showed that 3n potently inhibited hCYP1B1 via a mix inhibition manner, showing a Ki value of 21.71 pM. Docking simulations suggested that introducing a pyrimidine moiety to the hit compound (1d) facilitated 3n to form two strong interactions with hCYP1B1/heme, viz., the C-Br⋯π halogen bond and the N-Fe coordination bond. Further investigations demonstrated that 3n (5 μM) could significantly reverse the paclitaxel (PTX) resistance in H460/PTX cells, evidenced by the dramatically reduced IC50 values, from 632.6 nM (PTX alone) to 100.8 nM (PTX plus 3n). Collectively, this study devised a highly potent hCYP1B1 inhibitor (3n) without AhR agonist effect, which offered a promising drug candidate for overcoming hCYP1B1-associated drug resistance.

Benzo[c][2,7]naphthyridines As Inhibitors of PDK-1

Design, Synthesis and Biological Evaluation of Novel Pyrimidinedione Derivatives As DPP-4 Inhibitors.

Design, Synthesis and Biological Evaluation of Thienopyridinones As Chk1 Inhibitors

Identification of Novel Thiazolo[5,4-<i>b</i>]Pyridine Derivatives as Potent Phosphoinositide 3-Kinase Inhibitors

Imidazo[1,2-b]pyridazines as inhibitors of DYRK kinases

Discovery of 2,6-disubstituted pyrazine derivatives as inhibitors of CK2 and PIM kinases.

Structural Investigations on 2-Amidobenzimidazole Derivatives as New Inhibitors of Protein Kinase CK1 Delta

Design and synthesis of novel fluorene derivatives as inhibitors of pyruvate dehydrogenase kinase

Structure-based Design and SAR Development of 5,6-Dihydroimidazolo[1,5-f]pteridine Derivatives As Novel Polo-like Kinase-1 Inhibitors.

Molecular structures of cdc2-like kinases in complex with a new inhibitor chemotype

Synthesis, biological evaluation and structure-activity relationship of novel dichloroacetophenones targeting pyruvate dehydrogenase kinases with potent anticancer activity

Discovery of Novel Naphthoquinone Derivatives As Inhibitors of the Tumor Cell Specific M2 Isoform of Pyruvate Kinase.

Aromatic Diacylhydrazine Derivatives As a New Class of Polo-Like Kinase 1 (PLK1) Inhibitors.

Design, Synthesis, Biological Evaluation, and Molecular Docking of Novel Benzopyran and Phenylpyrazole Derivatives as Akt Inhibitors.

Design, synthesis and structure-activity relationship of 1,8-naphthalimide derivatives as highly potent hCYP1B1 inhibitors

Development of the First Generation of Disulfide-Based Subtype-Selective and Potent Covalent Pyruvate Dehydrogenase Kinase 1 (PDK1) Inhibitors

Structure-activity Relationship Investigation for Benzonaphthyridinone Derivatives As Novel Potent Bruton's Tyrosine Kinase (BTK) Irreversible Inhibitors.

Synthesis, spectroscopic characterization, DFT and molecular docking of N-(3-cyano-4,5,6,7-tetrahydrobenzo[b]thiophen-2-yl) naphthalene-1-sulfonamide derivatives

Design, synthesis, crystallographic studies, and preliminary biological appraisal of new substituted triazolo[4,3-b]pyridazin-8-amine derivatives as tankyrase inhibitors

Discovery of Substituted 1H-Pyrazolo[3,4-b]pyridine Derivatives As Potent and Selective FGFR Kinase Inhibitors.

Synthesis of Triazole-Linked Beta-C-glycosyl Dimers As Inhibitors of PTP1B.